+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer

Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer

Breast Cancer 21(1): 66-74

Although triple-negative breast cancer (TNBC) with epidermal growth factor receptor (EGFR) expression has been extensively studied, few studies have simultaneously examined EGFR expression and EGFR gene amplification. Here, we examined the correlations of EGFR expression with EGFR gene amplification, EGFR-activating mutations, and the expression of components of the Akt pathway. Tumor tissues were obtained from 84 patients with TNBC. We analyzed the expression of EGFR, phosphorylated Akt (p-Akt), phosphorylated mammalian target of rapamycin (p-mTOR), and other relevant proteins using immunohistochemistry. We also analyzed EGFR gene and chromosome 7 copy numbers by dual-color in situ hybridization. DNA was extracted from formalin-fixed paraffin-embedded samples. Analysis of EGFR gene-activating mutations was performed using the smart amplification process version 2 assay. Most TNBCs expressing EGFR are non-specialized invasive ductal carcinomas, whereas others are likely to be rare specialized carcinomas, such as typical medullary carcinoma, apocrine carcinoma, metaplastic carcinoma, and adenoid cystic carcinoma. EGFR was expressed in samples from 28 of 84 (33.3%) patients, but the EGFR gene was not amplified in any of the 84 samples. There were significant correlations between EGFR expression and the number of polysomic cells and the presence of high polysomy of chromosome 7. However, EGFR expression was not correlated with p-Akt or p-mTOR expression, nor with the other clinicopathological factors recorded in this study. We found no evidence of EGFR gene-activating mutations. EGFR gene amplification and EGFR-activating mutations might not be the mechanisms leading to the constitutive activation of EGFR in TNBC. Further investigation is needed to clarify the other molecular mechanisms for oncogenic activation of EGFR in TNBC.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036377820

Download citation: RISBibTeXText

PMID: 22481575

DOI: 10.1007/s12282-012-0354-1

Related references

Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncology Reports 14(2): 337-343, 2005

EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number. Ceskoslovenska Patologie 51(2): 80-86, 2016

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Targeted Oncology 9(4): 349-357, 2015

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern Pathology 18(8): 1027-1033, 2005

Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients. Zhonghua Yi Xue Za Zhi 96(12): 940-943, 2017

Human epidermal growth factor receptor 1 (EGFR) expression was not associated with gene amplification but intimately assoclated with HER2 gene amplification and protein expression in tissue microarray of clinical breast cancers. European Journal of Cancer Suppl.s 4(2): 122-123, 2006

EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Medical Oncology 29(2): 401-405, 2012

Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer. Tumour Biology 35(10): 9751-9757, 2015

Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification. Human Pathology 41(11): 1617-1623, 2010

EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genetics and Cytogenetics 203(2): 222-229, 2011

Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. Bmc Clinical Pathology 12: 18, 2012

Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients. Diagnostic Pathology 6: 57, 2011

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. Breast Cancer Research and Treatment 170(2): 351-360, 2018

Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer. Annals of Diagnostic Pathology 28: 43-53, 2018

Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. Plos One 7(2): E31070, 2012